2015 Plenary Keynote Program:
Wednesday, September 23 beginning at 12:55pm
The fundamental challenge for getting drugs to market sooner and cheaper is how best to judge and predict the success of drug candidates as efficiently and accurately as possible. In our Plenary Keynote session we will hear two cutting edge approaches for tackling this problem: Dr. Jaenisch explains how new gene-editing tools such as CRISPR can improve 'disease-in-a-dish' models enabled by iPS (induced pluripotent stem cell) technology. Dr. Nowak will discuss how mathematical-based evolutionary theory can be applied to understanding cancer.
12:55 EVENT CHAIRPERSON'S OPENING REMARKS
Cindy Crowninshield, RDN, LDN, Senior Conference Director, Cambridge Healthtech Institute
1:00 PLENARY KEYNOTE INTRODUCTION:
Comprehensive Kinase and Epigenetic Compound Profiling
Kelvin Lam, Ph.D., Director, Strategic Partnerships, Reaction Biology Corporation
Kinase inhibitors can be used as chemical probes to understand signal transduction pathways. Since the majority of kinase probes inhibit multiple kinases, understanding the off-target effects will allow scientists to design better poly-pharmacologic compounds to meet specific therapeutic needs. Profiling a compound against the entire kinase gene family will allow us to understand the compound’s full enzymatic activities. Unexpected activities could lead to different chemical design and possibly novel therapeutic opportunities. Reaction Biology offers large-scale in vitro kinase and epigenetic profiling services for (1) compound prioritizing and (2) elucidating novel activities for kinase and epigenetic inhibitors.
1:15 PLENARY KEYNOTE SPEAKER:
iPS Cell Technology, Gene Editing and Disease Research
Rudolf Jaenisch, M.D., Founding Member, Whitehead Institute for Biomedical Research; Professor, Department of Biology, Massachusetts Institute of Technology
The development of the iPS cell technology has revolutionized our ability to study human diseases in defined in vitro cell culture systems. A major problem of using iPS cells for this “disease in the dish” approach is the choice of control cells because the unpredictable variability between different iPS / ES cells to differentiate into a given lineage. Recently developed efficient gene editing methods such as the CRISPR/Cas system allow the creation of genetically defined models of monogenic as well as polygenic human disorders.
1:55 PLENARY KEYNOTE SPEAKER:
The Evolutionary Dynamics and Treatment of Cancer
Martin Nowak, Ph.D., M.Sc., Professor, Biology and Mathematics and Director,
Program for Evolutionary Dynamics, Harvard University
Cancer is an evolutionary process. Cancer initiation and progression are caused by
somatic mutation and selection of dividing cells. The mathematical theory of evolution can
therefore provide quantitative insights into human cancer.
2:35 Q&A/Closing Comments
2:40 Refreshment Break in the Exhibit Hall with Poster Viewing